NAFLD is associated with metabolic risk factors such as obesity, metabolic syndrome, dyslipidemia
, insulin resistance (IR) and type 2 diabetes7.
Pharmaceutical company Zydus revealed on Friday the receipt of marketing approval for the commercialisation of Lipaglyn (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia
in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.
The status of several trace metals such as copper, iron and manganese has been suggested to be associated with dyslipidemia
(1); however, most of the data to this respect come from studies in animals (1-4).
The results were unveiled today as part of the official symposium of the 77 Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA, titled, "Inhibition of PCSK9 in Dyslipidemia
Patients with Diabetes.
Increased frequency of dyslipidemia
was noticed in those subjects who had proteinuria >1gm (P value 18yrs old and fulfilled the ACR classification criteria for SLE with renal involvement either biopsy proven or had proteinuria, hematuria or an elevated serum creatinine.
Compared with the 13% to 18% estimated high total cholesterol prevalence in the US adult general population, dyslipidemia
prevalence in HIV-positive adults in the United States, Switzerland, and Spain ranges from 23% in a large study at two Boston hospitals (Table 2) (21) to 67% among women and 81% among men in the US HIV Outpatient Study (HOPS) (Table 1).
The prevalence of dyslipidemia
in patients with LP was 38% for cases and 6% for controls (p value< 0.
Considering that the surface with activated platelets is a "buffer state" for all hemostasis processes , capable of causing occlusion of different vessels [33,34] under poor disaggregating mechanisms, experimental works on the detailed study of the dyslipidemia
impact on platelet activity are considered to be of great practical interest.
Visit the Dyslipidemia
Drugs Market - Global Dyslipidemia
Drug Classes Analysis and Forecast 2013-2020 report at http://www.
Additionally, the report provides an overview of key players involved in therapeutic development for Mixed Dyslipidemia
and features dormant and discontinued projects.
is a term to lipoprotein abnor-malities including elevated serum Triglycerides (TG), increased Total Cholesterol (TC), increased LDL-cho-lesterol (LDL), increased VLDL colesterol, and a redu-ced level of HDL-cholesterol (HDL).
The World Health Organization (WHO) estimates that dyslipidemia
is associated with more than half of the global cause of ischemic heart diseases.